Prognostic value of cell adhesion in esophageal adenocarcinomas

Diseases of the Esophagus

Volumn 21, Issue 2, 2008, Pages 97-102

  Falkenback, D ^a   Nilbert, Mef ^a   Oberg S ^a   Johansson, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenocarcinoma; Barrett's esophagus; E cadherin; Immunohistochemistry; Prognosis

Indexed keywords

BETA CATENIN; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER; UVOMORULIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CELL ADHESION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; AGED; BETA CATENIN; CADHERINS; CELL ADHESION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049139719     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00749.x     Document Type: Article

References (33)

1. Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
2. Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
3. Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
4. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright T M. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999; 50: 23-6.
5. Montgomery E. Is there a way for pathologists to decrease interobserver variability in the diagnosis of dysplasia? Arch Pathol Lab Med 2005; 129: 174-6.
6. McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004; 64: 1561-9.
7. Fléjou J F. Barrett's oesophagus. From metaplasia to dysplasia and cancer. Gut 2005; 54: I6-12.
8. Koppert L B, Wijnhoven B P L, van Dekken H, Tilanus H W, Dinjens W N M. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005; 92: 169-90.
9. Reid B J, Prevo L J, Galipeau P C et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-48.
10. Casson A G, Manolopoulus B, Troster M et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 1994; 167: 52-7.
11. Bian Y S, Osterheld M C, Bosman F T, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 2001; 14: 397-403.
12. Woodward T A, Klingler P D V, Genko P, Wolfe J T. Barrett's esophagus, apoptosis and cell cycle regulation. Correlation of p53 with Bax, Bcl-2 and p21 protein expression. Anticancer Res 2000; 20: 2427-32.
13. Dolan K, Walker S J, Gosney J, Field J K, Sutton R. TP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus 2003; 16: 83-9.
14. Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinomas: An immunohistochemical and immunoblot study. Am J Gastroenterol 1995; 90: 1808-13.
15. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152: 135-44.
16. Feith M, Stein H J, Mueller J, Siewert J R. Malignant degeneration of Barrett's esophagus: The role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 2004; 17: 322-7.
17. Washington K, Chiappori A, Hamilton K et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998; 11: 805-13.
18. Bongiorno P F, al-Kasspooles M, Lee S W et al. E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus. Br J Cancer 1995; 71: 166-72.
19. Andl C D, Fargnoli B B, Okawa T et al. Coordinated functions of E-cadherin and transforming growth factor receptor II in vitro and in vivo. Cancer Res 2006; 66: 9878-85.
20. Guo M, Ren J, House M G, Qi Y, Brock M V, Herman J G. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 2006; 12: 4515-22.
21. Anderson M R, Harrison R, Atherfold P A et al. Met receptor signaling: A key effector in esophageal adenocarcinomas. Clin Cancer Res 2006; 12: 5936-42.
22. Krishnadath K K, Tilanus H W, van Blankenstein M et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182: 331-8.
23. Osterheld M C, Bian Y S, Bosman F T, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002; 117: 451-6.
24. Research Committee on malignancy of esophageal cancer, Japanese Society for Esophageal Diseases. Prognostic significance of cyclin D1 and E-cadherin in patients with esophageal squamous cell carcinoma: multi-institutional retrospective analysis. J Am Coll Surg 2001; 192: 708-18.
25. Nair K S, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 2005; 58: 343-51.
26. Wijnhoven B P, Pignatelli M, Dijnens W N, Tilanus H W. Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol 2005; 92: 116-23.
27. Park S, Kim S W, Lee B L, Jung E J, Kim W H. Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. Hepatogastroenterology 2006; 53: 28-32.
28. Imdahl A, Jenkner J, Ihling C, Rückauer K D, Farthmann E H. Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Am J Surg 2000; 179: 514-20.
29. Doak S H, Jenkins G J, Parry E M et al. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer 2003; 89: 1729-35.
30. Schneider P M, Stoeltzing O, Roth J A et al. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2000; 6: 3153-8.
31. Casson A G, Evans S C, Gillis A et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003; 125: 1121-31.
32. Ribeiro U, Finkelstein S D, Safatle-Riberio A V et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7-18.
33. Coggi G, Bosari S, Roncalli M et al. p53 protein accumulation and p53 mutation in esophageal carcinoma: A molecular and immunohistochemical study with clinicopathologic correlation. Cancer 1997; 79: 425-32.